BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 26304876)

  • 1. Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
    Goldstein DA; El-Rayes BF; Chen Q; Flowers CR
    J Clin Oncol; 2015 Nov; 33(32):3842-3. PubMed ID: 26304876
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
    Saltz LB
    J Clin Oncol; 2015 Nov; 33(32):3843-4. PubMed ID: 26304894
    [No Abstract]   [Full Text] [Related]  

  • 3. Costs of chemotherapy in the treatment of colorectal cancer.
    Jansman FG; Postma MJ
    Eur J Health Econ; 2006 Jun; 7(2):145-6. PubMed ID: 16699776
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab Plus Chemotherapy Cost Effectiveness.
    Bordonaro R; Cordio S; Uccello M; Martines C; Fassari GE
    J Clin Oncol; 2015 Nov; 33(32):3840-1. PubMed ID: 26304880
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.
    Messori A; De Rosa M; Fadda V; Pani L
    J Clin Oncol; 2015 Nov; 33(32):3838-9. PubMed ID: 26304897
    [No Abstract]   [Full Text] [Related]  

  • 6. Can money really be no object when cancer care is the subject?
    Saltz LB
    J Clin Oncol; 2015 Apr; 33(10):1093-4. PubMed ID: 25691668
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution.
    Fasola G; Aprile G; Pinto C
    J Clin Oncol; 2015 Nov; 33(32):3841-2. PubMed ID: 26304899
    [No Abstract]   [Full Text] [Related]  

  • 8. ["The expensive" health care. Sneaky rationing or ration book?!].
    Breimer L
    Lakartidningen; 2015 Apr; 112():. PubMed ID: 25898381
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to U.R. Mansmann et al and M.-W. An et al.
    Claret L; Bruno R
    J Clin Oncol; 2013 Dec; 31(34):4374-5. PubMed ID: 24166517
    [No Abstract]   [Full Text] [Related]  

  • 10. [The debate on ethics, law and new expensive drugs. Speak clearly about health care limitations].
    Bratt O
    Lakartidningen; 2015 Jun; 112():. PubMed ID: 26126014
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B; Cantagalli E; Amalfitano ME
    Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract]   [Full Text] [Related]  

  • 12. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Goldstein DA; El-Rayes BF
    Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 14. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Y. Sunakawa et al and P. Mroczkowski et al.
    Ye LC; Zhong YS; Lin Q; Xu J
    J Clin Oncol; 2013 Dec; 31(35):4474-5. PubMed ID: 24166525
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
    Nelson MA; Shetty S; Kulakodlu M; Harley C; Seal B
    J Med Econ; 2011; 14(2):179-86. PubMed ID: 21319948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
    Franken MD; Koopman M; van Oijen MG
    Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to S. Debska-Szmich et al.
    Van Cutsem E; Beier F; Ciardiello F
    J Clin Oncol; 2015 Oct; 33(30):3518. PubMed ID: 26304910
    [No Abstract]   [Full Text] [Related]  

  • 19. [Costs, disease management and DRG].
    Barni S; MandalĂ  M; Gambera M
    Tumori; 2001; 87(1 Suppl 1):S59. PubMed ID: 11300029
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
    Chu E; Cartwright TH
    J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.